Riskpilot← Back to searchSign inGet full accessAnemone Hepatica AB
ABDissolvedOrg 5567343479LundRetail sale of flowers, plants, fertilisers, pets and pet food · NACE 4776Est. 20071 employees
Revenue 2024
SEK 3M
-28% vs 2023
EBITDA margin
18.6%
+147% vs 2023
Equity ratio
89.2%
Financial strength
Net profit 2024
SEK 444K
+148% vs 2023
| Revenue | SEK 3M | -28% |
| EBITDA | SEK 559K | +147% |
| Net profit | SEK 444K | +148% |
| Total assets | SEK 977K | +4% |
| Equity | SEK 871K | +58% |
| Employees | 1 | — |
Legal name
Anemone Hepatica AB
Org number
5567343479
Legal form
Aktiebolag
NACE code
4776 · Retail sale of flowers, plants, fertilisers, pets and pet food
Founded
5 juli 2007
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Bolaget ska bedriva aktie- och kapitalförvaltning samt därmed förenlig verksamhet.
Address
Lund
Email
info@bolagspartner.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 596 | 4 880 | 4 683 | 4 154 | 3 003 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 459 | 203 | 216 | 226 | 559 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 459 | 203 | 216 | 226 | 559 |
| Net financials | — | — | — | 1 | 2 |
| Profit before tax | 458 | 203 | 215 | 227 | 561 |
| Tax | −99 | −45 | −46 | −48 | −117 |
| Net profit | 359 | 158 | 169 | 179 | 444 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 129 | 1 033 | 962 | 935 | 977 |
| Equity | 596 | 454 | 374 | 552 | 871 |
| Long-term debt | 0 | 0 | 0 | 0 | 63 |
| Short-term debt | 533 | 579 | 588 | 383 | 43 |
| Total debt | 533 | 579 | 588 | 383 | 106 |
EBITDA margin
18.6%
This company
15.8%
Market median
+18% vs market
20202024
Equity ratio
89.2%
This company
38.2%
Market median
+134% vs market
20202024
Return on equity
51.0%
This company
18.4%
Market median
+177% vs market
20202024
Net profit margin
14.8%
This company
8.1%
Market median
+83% vs market
20202024
Asset turnover
3.07×
This company
1.12×
Market median
+174% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Audit | 2022 – 2025 | |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Anemone Hepatica AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Ludvigh Stensson Nyström | Audit | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Karl-Johan Staffan Tångby | Board of Directors | 0 companies |
| Mats Roland Hein | Deputy Board Member | 0 companies |
| Inga-Sofie Johanna Hein | Board of Directors | 0 companies |